Skip to main content

PGDx Raises $103M in Third Mega Deal of 2021

Baltimore City's Personal Genome Diagnostics (PGDx) has raised $103 million in Series C funding to "go out and sell" its groundbreaking cancer diagnostic technology. The company received FDA clearance for its diagnostic test kit in April 2020; the kit is designed to provide a genomic profile of tissue from a cancer patient. This is Greater Baltimore's third "mega-deal" of more than $100 million in 2021, following SparkPost and Delfi Diagnostics. Via Baltimore Business Journal.

Read More

Subscribe to our mailing list: